{
    "clinical_study": {
        "@rank": "73923", 
        "arm_group": {
            "arm_group_label": "SGN-LIV1A", 
            "arm_group_type": "Experimental", 
            "description": "SGN-LIV1A every 3 weeks by intravenous infusion"
        }, 
        "brief_summary": {
            "textblock": "This study is being conducted to examine the safety and tolerability of SGN-LIV1A in\n      patients with metastatic breast cancer, and to find the highest dose of the drug that can be\n      given without unacceptable side effects.  Other goals of the trial are to find out if\n      SGN-LIV1A has any antitumor effects, to learn about the pharmacokinetics of SGN-LIV1A, and\n      to explore the relationship between antigen expression and SGN-LIV1A effects."
        }, 
        "brief_title": "A Safety Study of SGN-LIV1A in Breast Cancer Patients", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically confirmed diagnosis of breast cancer with radiographic evidence of\n             metastatic disease\n\n          -  One of the following: a) Triple-negative disease (ER/PR/HER2-negative) and received\n             at least 2 prior cytotoxic regimens in the metastatic setting; or b) ER- and/or\n             PR-positive/HER2-negative disease and received at least 2 prior cytotoxic regimens in\n             the metastatic setting and are no longer a candidate for hormonal therapy\n\n          -  Positive for LIV-1 expression by central pathology review on newly obtained tumor\n             tissue biopsy\n\n          -  Measurable disease\n\n          -  Eastern Cooperative Oncology Group performance status 0 or 1\n\n        Exclusion Criteria:\n\n          -  Pre-existing neuropathy Grade 2 or higher\n\n          -  Malignant CNS disease that has not been definitively treated\n\n          -  P-gp inducers/inhibitors or strong CYP3A inducers/inhibitors within 2 weeks before\n             first dose"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "51", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969643", 
            "org_study_id": "SGNLVA-001"
        }, 
        "intervention": {
            "arm_group_label": "SGN-LIV1A", 
            "description": "by intravenous infusion every 3 weeks", 
            "intervention_name": "SGN-LIV1A", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Breast cancer", 
            "Monomethyl auristatin E", 
            "Antibody-drug conjugate", 
            "Drug therapy", 
            "Metastatic", 
            "LIV-1 protein, human"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "djmartin@uab.edu", 
                    "last_name": "Deborah Martin", 
                    "phone": "205-975-3198"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294-3300"
                    }, 
                    "name": "University of Alabama at Birmingham"
                }, 
                "investigator": {
                    "last_name": "Andres Forero-Torres, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "virginia.naessig@cshs.org", 
                    "last_name": "Virginia Naessig", 
                    "phone": "310-423-0721"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Cedars-Sinai Medical Center / Samuel Oschin Comprehensive Cnacer Institute"
                }, 
                "investigator": {
                    "last_name": "Monica Mita, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "acgrist@iupui.edu", 
                    "last_name": "Ashley Grist", 
                    "phone": "317-278-6680"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Simon Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Kathy Miller, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zuccaroc@karmanos.org", 
                    "last_name": "Clarice Zuccaro", 
                    "phone": "313-576-9375"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Karmanos Cancer Institute / Wayne State University Department of Oncology"
                }, 
                "investigator": {
                    "last_name": "Patricia LoRusso, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "roos.michelle@mayo.edu", 
                    "last_name": "Michelle Roos", 
                    "phone": "507-538-7036"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Minetta Liu, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "heather.pedigo@scresearch.net", 
                    "last_name": "Heather Pedigo", 
                    "phone": "615-329-7432"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "investigator": {
                    "last_name": "Howard Burris III", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mollerup@u.washington.edu", 
                    "last_name": "Audrey Mesher", 
                    "phone": "206-288-2056"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109-1023"
                    }, 
                    "name": "Seattle Cancer Care Alliance / University of Washington"
                }, 
                "investigator": {
                    "last_name": "Jennifer Specht, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "clinicaltrials@seagen.com", 
            "last_name": "Terri Lowe", 
            "phone": "866-333-7436"
        }, 
        "overall_official": {
            "affiliation": "Seattle Genetics, Inc.", 
            "last_name": "Ana Kostic, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Through 1 month following last dose"
            }, 
            {
                "measure": "Incidence of laboratory abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Through 1 month following last dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969643"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Blood concentrations of SGN-LIV1A and metabolites", 
                "safety_issue": "No", 
                "time_frame": "Through 3 weeks after dosing"
            }, 
            {
                "measure": "Incidence of antitherapeutic antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Through 1 month following last dose"
            }, 
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "Through 1 month following last dose"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 3 years"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 3 years"
            }, 
            {
                "measure": "Progression-free survival relative to prior therapy", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 3 years"
            }
        ], 
        "source": "Seattle Genetics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seattle Genetics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}